Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine ... disease and pneumonia caused by Streptococcus pneumoniae in people aged ...

Strep throat is a highly contagious infection caused by group A Streptococcus bacteria (Streptococcus pyogenes); it is common in children but affects adults too. Strep throat symptoms include a sore ...

The 21-valent product – formerly known as V116 – covers a wider range of Streptococcus pneumoniae serotypes than any of MSD’s earlier vaccines and eight that are not covered by any other ...

The ensuing tissue damage is integral to pneumococcal disease (22). For example ... low-PLY producing bacteria facilitated evasion of host defense mechanism and promoted the cross of the blood-brain ...

The pneumococcal conjugate vaccine – codenamed PCV21/GBP410 – has started pivotal trials in the prevention of both paediatric Streptococcus pneumoniae, which remains a major public health ...

Recurring strep throat describes a group A Streptococcus bacterial infection that occurs more than once during a respiratory season. Recurring strep throat happens more often in children and is ...

"Getting his blood clean, making sure his kidneys are okay. But his lungs... he's on an antibiotic to get rid of the strep pneumoniae, but the lungs are the very last thing that will happen." ...

PCV protects against infections caused by streptococcus pneumoniae, a leading cause of serious illnesses such as pneumonia, meningitis, and sepsis, particularly among children under five.

With the results of control programs for contagious mastitis (Staphylococcus aureus, Streptococcus agalactiae and Mycoplasma spp ... Molecular analysis. K. pneumoniae DNA was extracted by using the ...